EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Dry Powder Inhalers in the Age of Digital Health: Current Status, Regulatory Considerations and Future Perspectives

Chinna Reddy Palem, Praveen Rao Balguri, Vamshi Krishna Lekkala, Nishanth Kumar Nagamalli, Sridhar Gumudevelli

International Journal of Medical Sciences and Pharma Research · 15.03.2026 · 12 (1) · 1-10

DOI: 10.22270/ijmspr.v12i1.169 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Medical Sciences and Pharma Research, online erschienen am 15.03.2026. Verfasst von Chinna Reddy Palem und 4 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dry powder inhalers (DPIs) are established drug–device combination products in which therapeutic performance is governed by the interaction between formulation properties, device engineering, and patient-specific inhalation behavior. Although advances in particle engineering and inhaler design have improved dose delivery and aerosol performance, real-world effectiveness remains limited by variability in inspiratory flow, inhalation technique, and disease state. These challenges underscore the need for a systems-based approach that recognizes DPIs as integrated delivery platforms rather than conventional dosage forms. The emergence of digital health technologies, including embedded sensors, connectivity, data analytics, and software-driven feedback, has enabled the development of digitally enabled or “smart” DPIs. Such products have the potential to function as connected combination products, supporting inhalation monitoring, adherence assessment, and personalized therapy. From a regulatory perspective, the integration of digital components introduces considerations related to software as a medical device (SaMD), data integrity, cybersecurity, interoperability, and lifecycle management, as outlined in evolving FDA and EMA digital health and combination product frameworks. This review summarizes the current status of DPI technology in the context of digital health integration, with emphasis on formulation–device–patient interactions, clinically relevant digital functionalities, and performance evaluation. Key regulatory expectations for development, validation, and post-market oversight of digital DPIs are discussed, including alignment with quality by design and risk-based regulatory approaches. Finally, future perspectives are presented to identify scientific and regulatory gaps that must be addressed to enable next-generation digital DPIs capable of delivering reliable, patient-centric, and outcome-driven inhalation therapy. Keywords: Dry powder inhalers; Digital health technologies; Software as a medical device; Regulatory consideration; Quality by design

Zitieren

APA

Palem, C. R., Balguri, P. R., Lekkala, V. K., Nagamalli, N. K., & Gumudevelli, S. (2026). Dry Powder Inhalers in the Age of Digital Health: Current Status, Regulatory Considerations and Future Perspectives. International Journal of Medical Sciences and Pharma Research, 12(1), 1-10. https://doi.org/10.22270/ijmspr.v12i1.169

Vancouver

Palem CR, Balguri PR, Lekkala VK, Nagamalli NK, Gumudevelli S. Dry Powder Inhalers in the Age of Digital Health: Current Status, Regulatory Considerations and Future Perspectives. International Journal of Medical Sciences and Pharma Research. 2026;12(1):1-10. doi:10.22270/ijmspr.v12i1.169

BibTeX
@article{Palem2026,
  author = {Palem, Chinna Reddy and Balguri, Praveen Rao and Lekkala, Vamshi Krishna and Nagamalli, Nishanth Kumar and Gumudevelli, Sridhar},
  title = {Dry Powder Inhalers in the Age of Digital Health: Current Status, Regulatory Considerations and Future Perspectives},
  journal = {International Journal of Medical Sciences and Pharma Research},
  year = {2026},
  volume = {12},
  number = {1},
  pages = {1--10},
  doi = {10.22270/ijmspr.v12i1.169}
}
Kostenlos starten →